Even in haemodialysis, patients with severely impaired kidneys need highly professional care to control calcium phosphate levels and vitamin D deficiency, so they can avoid renal osteodystrophy (ROD) and secondary hyperparathyroidism.

Defective kidneys cannot hydroxylate pro-vitamin D so that calcium in the digestive system can be absorbed into the bloodstream. With less calcium in the blood, the parathyroid gland produces parathyroidhormone (PTH) which raises calcium levels in the blood and suppresses phosphate levels.

Persistent low levels of calcium and high levels of phosphate cause secondary hyperparathyroidism, in which calcium is mobilised from the bones. This will lead to renal osteodystrophy (ROD), a potentially painful condition that puts patients at risk from bone fracture.

Treating conditions in nephrology
At LEO Pharma, we have 30 years of experience in helping healthcare professionals care for patients with impaired renal functions – and to help them avoid secondary hyperparathyroidism and ROD. Our products exist in several formulations to meet individual needs.

On the market since 1978, LEO Pharma’s vitamin D analogue is a widely used product, administered to a large percentage of patients with impaired renal function. A huge body of knowledge in clinical practice documents the use of our vitamin D analogue. 

LEO Pharma is dedicated to continue helping healthcare professionals give their haemodialysis patients the optimal treatment. That is why we are focused on providing new products in nephrology.